Liposome immunoadjuvants containing IL-2

• US 5,650,152 A
• Filed: 12/10/1993
• Issued: 07/22/1997
• Est. Priority Date: 10/27/1988
• Status: Expired due to Fees

• Current Assignee: Oncothyreon Incorporated
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Leonard, Arnold S., Anderson, Peter M., Ochoa, Augusto C., Loeffler, Cynthia
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Minnifield, N. M.
• Application Number:
  US08/164,746
• Time in Patent Office: 1,320 Days
• Field of Search: 424/812, 424/184.1, 424/155.1, 424/208.1, 424/234.1, 424/204.1, 424/201.1, 424/200.1, 424/275.1, 424/195.11, 424/450, 424/283.1, 424/423
• US Class Current: 424/195.11
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 2039/55533 IL-2
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2239/50 Colon
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: A61K 39/292 Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C12N 2730/10134 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: Y10S 424/812 : Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Abstract

The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.

Claims

1. A vaccine comprising an immunogenically effective amount of a non-liposomally-entrapped vaccine antigen and an effective immunoadjuvant amount of liposomally-entrapped interleukin-2 (IL-2) in combination with a pharmaceutically acceptable liquid vehicle.

2. The vaccine of claim 1 wherein said vaccine antigen is derived from bacteria, parasites, viruses, or rickettsia.

3. The vaccine of claim 2 wherein the antigen is derived from a bacteria selected from the group consisting of H. pertussis, Leptospira pomona, Leptospira icterohaemorrhagiae, S. typhosa, S. paratyphi A, S. paratyphi B, C. diphtheriae, C. tetani, C. botulinum, C. perfringens, C. feseri, B. anthracis, P. pestis, P. multocida, V. cholerae, and mycobacteria.

4. The vaccine of claim 2 wherein the antigen is derived from C. tetani.

5. The vaccine of claim 2 wherein the antigen is derived from a virus selected from the group consisting of poliovirus, adenovirus, parainfluenza virus, measles, mumps, respiratory syncytial virus, influenza, shipping fever virus (SF4), hepatitis B, retroviruses, Western and Eastern equine encephalomyelitis, Japanese B. encephalomyelitis, Russian Spring Summer encephalomyelitis, hog cholera virus, hoof and mouth disease, fowl pox, Newcastle disease virus, rabies, feline distemper, and canine distemper.

6. The vaccine of claim 5 wherein the antigen is derived from hepatitis B.

7. The vaccine of claim 2 wherein said antigen is derived from a parasite selected from the group consisting of Lyme disease, malaria, schistosomiasis, leshmeniasis, cysticercosis, and fluke parasites.

8. The vaccine of claim 1 wherein the vaccine antigen is a tumor antigen.

9. The vaccine of claim 8 wherein said tumor antigen is derived from a tumor selected from the group consisting of lung cancer, colon cancer, melanoma, and neuroblastoma.

10. The vaccine of claim 1 wherein the vaccine antigen is an allergen.

11. The vaccine of claim 1 wherein the vaccine antigen is in the form of a poison or a venom derived from poisonous insects or reptiles.

12. A vaccine comprising (1) an immunogenically effective amount of a non-liposomally-entrapped vaccine antigen;

(2) an effective immunoadjuvant amount of liposomally-entrapped interleukin-2 (IL-2), wherein said lipsomally-entrapped IL-2 comprises liposomal lipid, IL-2 and a protein carrier and the carrier;

liposomal lipid ratio (w/w) is from 1;

2 to 1;

12; and

(3) a pharmaceutically acceptable liquid vehicle.